OmniAb, Inc.
Sam (Baisen) Zeng has a strong background in scientific research, with a focus on biotechnology and biomolecular structures. Sam (Baisen) is currently working as a Senior Research Scientist at OmniAb, Inc., a position they have held since November 2022. Prior to this, they worked at Ligand Pharmaceuticals, where they started as a Research Scientist in July 2020 and was promoted to Senior Research Scientist in September 2022 before joining OmniAb, Inc.
Before joining Ligand Pharmaceuticals, Sam held various roles at the Center for Biomolecular Structure and Dynamics, starting as a Staff Scientist/Interim Core Manager in January 2019 and working until July 2020. In this role, they collaborated with core facility users and provided technical assistance in the Protein Expression Core and X-Ray Crystallography Core.
Sam's extensive research experience dates back to their time as a Graduate Research Assistant at the University of Montana, where they worked from July 2011 to January 2019. Sam (Baisen) also gained research experience as an Undergraduate Research Assistant at the Robert Mondavi Institute and the Center of Neuroscience, UC Davis.
Their career in scientific research began as a Student Assistant Intern at Davis Oral and Maxillofacial Surgery in 2007.
Sam (Baisen) Zeng began their education in 2005 at the University of California, Davis, where they pursued a Bachelor of Science degree in Biochemistry & Molecular Biology. Sam (Baisen) completed their undergraduate studies in 2010.
Continuing their academic journey, Sam enrolled at the University of Montana in 2011. Sam (Baisen) dedicated the following seven years to their pursuit of a Doctor of Philosophy degree in Biochemistry, Biophysics, and Molecular Biology, which they successfully completed in 2018.
In summary, Sam (Baisen) Zeng obtained their Bachelor's degree in Biochemistry & Molecular Biology from the University of California, Davis in 2010. Afterward, they furthered their studies at the University of Montana and earned their Doctor of Philosophy degree in Biochemistry, Biophysics, and Molecular Biology in 2018.
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.